MC
ATRA icon

Maverick Capital’s Atara Biotherapeutics ATRA Stock Holding History

Maverick Capital’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-7,244
Closed -$268K – 360
2023
Q3 		$268K Hold
7,244
– – 0.01% 241
2023
Q2 		$292K Sell
7,244
-2,944
-29% -$166K 0.01% 355
2023
Q1 		$739K Buy
+10,188
New +$988K 0.02% 188

Other funds holding ATRA

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Maverick Capital's ATRA Position: Q4 2023 in Review

Maverick Capital sold out of Atara Biotherapeutics (ATRA) in Q4 2023, closing a stake of 251,629 shares — an estimated $9.31M sold.

Maverick Capital first reported a position in ATRA in Q1 2019 and held it in 19 quarters. The position peaked at $144M in Q4 2020. 89 funds tracked by Wall St. Rank hold ATRA as of Q4 2023.

  • Maverick Capital reported no remaining Atara Biotherapeutics position as of Q4 2023 after selling out during the quarter.
  • Maverick Capital sold 251,629 Atara Biotherapeutics shares in Q4 2023, an estimated $9.31M.
  • Maverick Capital first reported a position in Atara Biotherapeutics in Q1 2019 and held it in 19 quarters.
  • Maverick Capital's Atara Biotherapeutics position peaked at $144M in Q4 2020.
  • 89 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2023.

Based on Maverick Capital's 13F filing for Q4 2023, filed 14 Feb 2024.